Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
3,562
Total Claims
$5.3M
Drug Cost
440
Beneficiaries
$12K
Cost/Patient
Risk Score Breakdown 12/100
Score components are additive. Read full methodology
Peer Comparison vs. 8,541 Hematology-Oncology providers
+37%
Opioid rate vs peers
8.6% vs 6.3% avg
-12%
Cost per patient vs peers
$12K vs $14K avg
⚠️ Opioid + Benzodiazepine Co-Prescriber
This provider prescribes both opioids and benzodiazepines. The FDA has issued a Black Box Warning about the life-threatening risks of concurrent use.
Opioid Prescribing
8.6%
Opioid Rate
306
Opioid Claims
$23K
Opioid Cost
16.3%
Long-Acting Rate
Brand vs Generic
Brand: 0 claims · $0
Generic: 2,743 claims · $156K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Lenalidomide | 99 | $1.8M |
| Pomalidomide | 27 | $498K |
| Cabozantinib S-Malate | 18 | $481K |
| Palbociclib | 27 | $435K |
| Ibrutinib | 19 | $299K |
| Acalabrutinib Maleate | 18 | $271K |
| Ruxolitinib Phosphate | 13 | $246K |
| Osimertinib Mesylate | 11 | $196K |
| Rivaroxaban | 119 | $117K |
| Apixaban | 120 | $112K |
| Lipase/Protease/Amylase | 37 | $105K |
| Enzalutamide | 12 | $95K |
| Abiraterone Acetate | 13 | $30K |
| Naproxen | 14 | $29K |
| Fluticasone/Umeclidin/Vilanter | 21 | $14K |
Prescribing Profile
Patient Profile
75
Avg Age
57%
Female
2.37
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations.Methodology · About